Cytosorbents (CTSO) Tops Q3 EPS by 4c

Cytosorbents (NASDAQ: CTSO) reported Q3 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $5.79 million.

GUIDANCE:

We expect Q4 2018 product sales to exceed Q3 2018 product sales.

For earnings history and earnings-related data on Cytosorbents (CTSO) click here.

You May Also Be Interested In

• Crown Holdings (CCK) Tops Q2 EPS by 33c; offers outlook
• Eagle Nuclear Energy reports Q2 2026 update with $28.1M cash
• ServisFirst Bancshares (SFBS) Reports In-Line Q2 EPS